Cardiovascular and Metabolic Market Research and Competitive Intelligence Leaders
by
![]() |
![]() |
![]() |
![]() |
![]() |
CVrg Full Support™
CVrg Market Strategies™
CVrg Conference™
CVrg Sentinel™
CVrg Insights™
CVrg Advisory™
CVrg Full Support™
CVrg Market Strategies™
CVrg Conference™
CVrg Sentinel™
CVrg Insights™
CVrg Advisory™
About CVrg
Our Team
Careers
Contact
Home
CardioVascular
Acute Coronary Syndromes
Atrial Fibrillation & Stroke Prevention in AFib
Dyslipidemia/Atherosclerosis
Heart Failure
Peripheral Arterial Disease
Pulmonary Hypertension
Venous Thrombosis
Metabolic
Chronic Kidney Disease
Metabolic Dysfunction-Associated Steatohepatitis
Obesity
Type 1 Diabetes
Type 2 Diabetes
Conferences
ACC
EASL
ATS
HF-ESC
ERA
ADA
ESC
EASD
ERS
ASN
AASLD
AHA
ASH
Dr Schlaepfer has more than 25 years of scientific leadership and research accomplishments, including working in endocrinology for more than a decade and completing a Ph.D. in integrative physiology and genetics of addiction from the University of Colorado, Boulder. During her tenure at University of Colorado Medical School, she studied the role of lipids in insulin resistance and hormone-related cancers. Specifically, the combination of hormonal and metabolic inhibitors to reduce tumor growth and increase the sensitivity to standard of care treatments. Isabel brings to CVrg strong scientific and analytical skills, as well as interdisciplinary experience in biomedical research.